|
Market Closed -
Euronext Bruxelles
11:55:00 2026-10-06 EDT
|
5-day change | 1st Jan Change | ||
| 202.30 EUR | +0.70% |
|
-4.80% | -15.21% |
| 09-30 | Merck's experimental skin disease drug succeeds in mid-stage study | RE |
| 09-29 | UCB Presents Data From Innovative Myasthenia Gravis Portfolio At AANEM Annual Meeting And MGFA Scientific Session | CI |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
Compared values
| Sector | Change | 5-day change | YTD change | 1-year change | 5-year change | Capi. | ST | MT | LT | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| UCB | Biopharmaceuticals | +0.70% | -4.80% | -15.21% | -19.72% | +104.38% | 42.94B |  | | |
- Stock Market
- Stocks
- UCB Stock
- Charts UCB
- Comparison Chart
Select your edition
All financial news and data tailored to specific country editions
